Abbvie– M14-115 Serene, Protocol M14-115

A randomized, double-blind multicenter study of two adalimumab induction dosing regimens in subjects with moderately to severely active Crohn's disease and evidence of mucosal ulceration. (Abbvie)

Abbvie M14-347, Protocol M14-347

A multicenter, open-label study to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in subjects with Crohn's disease. (Abbvie)

Gilead/Galapagos Protocol GS-US-419-3895

A phase III, double blind, multi dose, placebo controlled, study to evaluate the efficacy and safety of Filgotinib in the induction and maintenance of remission in subjects with moderate to severe Crohn’s disease. (Gilead Sciences)

Janssen Stardust Protocol CNTO1275 CRD3005

A phase IIIB study of treat to target versus routine care maintenance strategies in Crohn's disease patients treated with ustekinumab. (Janssen Pharmaceutica NV)

Roche-Genentech Bergamot, Protocol GA29144

A phase III, multicenter, randomized, double-blinded placebo-controlled study to evaluate the efficacy and safety of etrolizumab (RO5490261) as an induction and maintenance treatment for patients with moderately to severely active Crohn’s disease (Roche-Genentech)

Roche-Genentech Juniper, Protocol GA29145

An open label extension study to evaluate the efficacy and safety of etrolizumab (RO5490261) for patients with moderately to severely active Crohn’s disease, treated in protocol GA29144. (Roche-Genentech)

Tigenix Admire CD II, Protocol Cx601-0303

A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn's disease over a period of 24 weeks and a follow up period up to 52 weeks. (Tigenix)

Love CD Study No 2014-100757

An open label interventional phase 4 study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in CD study) (Takeda) Investigator initiated study


Home basEd feacal calProtectin measurements predicting Adalimumab Induction Destiny. Investigator initiated study, Bird


Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Indution in patients with Crohn's disease and ulcerative colitis. Investigator initiated study, Bird

Connect IBD

Post-Marketing Observational Cohort study of patients with inflammatory bowel disease (IBD) treated with Inflectra. (Pfizer)


Copyright 2015 CIMW   |   | |     |   
Go to top